NMD Pharma
Presence
Acquisition, funding and merger involving NMD Pharma.
- NMD Pharma has just announced a $80 Million fundraising (posted on November 18 2023).
Executives
View the org chart displaying its 6 main executives
Most searched biographies at NMD Pharma
- Thomas Holm Pedersen, Chief Executive Officer
- Mike Heffernan, Chairman of the Board
- Daniel Brennan, Senior Vice President, Corporate and Commercial St...
Popular executive movements at NMD Pharma
- Morten Bull has joined the company as Senior Vice President, General Counsel and Head of People & Business Services (posted on January 23 2024).
Create your alert
to follow the executive moves at NMD Pharma.
Biotechnology
NMD Pharma has 2,290 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).
- Bluejay Therapeutics has just announced a $182 Million fundraising (posted on May 12 2024).
- Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
Popular contacts in Biotechnology
News
Press releases by NMD Pharma
- NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US — NMD Pharma
- NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine — NMD Pharma
- NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences — NMD Pharma
- NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services — NMD Pharma
- NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing — NMD Pharma
- NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society — NMD Pharma
- NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy — NMD Pharma
- NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association — NMD Pharma
- NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting — NMD Pharma
- NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy — NMD Pharma
- View more press releases Close
Social media about NMD Pharma
- NMD Pharma on Wikipedia, Google News & Yahoo Finance
- NMD Pharma on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Thomas Holm Pedersen 
